lifestyle.thedailyhaze.com

Author: Aspire Biopharma Holdings, Inc.

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam – Generic Xanax(R) – for Rapid Anxiety Relief

January 20, 2026
Aspire Biopharma Announces Reverse Stock Split

January 14, 2026
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

January 7, 2026
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

December 20, 2025
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

December 13, 2025